Darolutamide – Uses, Dosage, Side Effects, Interaction

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Darolutamide - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Mechanism of Action

The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than [apalutamide] and [enzalutamide], which are other androgen receptor antagonists. Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time.

Indications

  • This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer.
  • Nubeqa is indicated for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease.
  • Darolutamide is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral orchiectomy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men
  • Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate-specific antigen (PSA) levels through potent androgen receptor antagonism.
  • Darolutamide is an androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer.
  • Metastatic Hormone Sensitive Prostate Cancer
  • Non-mestatatic castrate-resistant prostate cancer

Use in Cancer

Darolutamide is approved to treat:

  • Prostate cancer. It is used in adults whose cancer:
    • Has spread to other parts of the body and responds to treatment that lowers testosterone levels. It is used with docetaxel.
    • Has not spread to other parts of the body and no longer responds to treatment that lowers testosterone levels.

Darolutamide is also being studied in the treatment of other types of cancer.

Contraindications

  • excessive fat in the blood
  • a low seizure threshold
  • high blood pressure
  • coronary artery disease
  • seizures
  • pregnancy
  • chronic kidney disease stage 4 (severe)
  • Child-Pugh class B liver impairment

Dosage

Strengths: 300 mg

Prostate Cancer

  • 600 mg orally 2 times a day
  • Patients receiving this drug should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • For nonmetastatic castration-resistant prostate cancer (nmCRPC)

Renal Dose Adjustments

  • Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended.
  • Severe renal impairment (CrCl 15 to 29 mL/min) who are not receiving hemodialysis: 300 mg orally 2 times a da
  • End-stage renal disease (CrCl 15 mL/min or less): Data not available

Liver Dose Adjustments

  • Mild (Child-Pugh A) hepatic impairment: No adjustment recommended.
  • Moderate (Child-Pugh B) hepatic impairment: 300 mg orally 2 times daily
  • Severe (Child-Pugh C) hepatic impairment: Data not available

Dose Adjustments

  • Grade 3 or greater toxicity or an intolerable adverse reaction: Withhold therapy or reduce to the dose to 300 mg 2 times a day until symptoms improve; then resume therapy at 600 mg orally 2 times a day.
  • Dose reduction below 300 mg orally 2 times a day is not recommended.

Administration advice:

  • This drug should be taken with food.
  • Swallow tablets whole; do not divide, crush, or chew.
  • If a dose is missed it should be taken as soon as it is remembered prior to the next scheduled dose; do not take 2 doses together to make up for a missed dose.

Side Effects

The Most Common

  • extreme tiredness
  • arm, leg, hand, or foot pain
  • arm, leg, hand, or foot pain
  • rash
  • blood in urine
  • fever, rapid and/or shallow breathing, or cough
  • chest pain or feeling of pressure in the chest
  • seizures
  • severe ongoing nausea or diarrhea;
  • painful or difficult urination;
  • blood in your urine;
  • severe pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache, blurred vision, pounding in your neck or ears;
  • slow heart rate, weak pulse, fainting, slow breathing (breathing may stop);
  • signs of a blood clot in the lung–chest pain, sudden cough, wheezing, rapid breathing, coughing up blood; or
  • signs of a lung infectionfever, chills, cough with mucus, chest pain, shortness of breath.

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine
  • bloody nose
  • blurred vision
  • coughing or spitting up blood
  • difficulty in breathing or swallowing
  • dizziness
  • frequent urination
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • increased menstrual flow or vaginal bleeding
  • lower abdominal or stomach cramping
  • nausea and vomiting
  • nervousness
  • nosebleeds
  • painful urination
  • paralysis
  • pounding in the ears
  • prolonged bleeding from cuts
  • red or dark brown urine
  • red or black, tarry stools
  • slow, fast, or irregular heartbeat
  • vomiting of blood or material that looks like coffee grounds
  • unusual bleeding or bruising

Rare

  • Blood in the urine
  • chest pain or discomfort
  • pain in the shoulders, arms, jaw, or neck
  • painful or difficult urination
  • seizures
  • sweating
  • trouble breathing
  • Constipation
  • decreased appetite
  • increased weight
  • pain in the arms or legs
  • rash
  • unusual tiredness or weakness
  • Chest pain or tightness
  • cough
  • fever or chills
  • muscle or bone pain
  • sneezing
  • sore throat

Drug Interaction

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

The safety and efficacy of this drug have not been established in females. Based on its mechanism of action, this drug can cause fetal harm and loss of pregnancy. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 1 week after. Based on animal studies, this drug may impair fertility in males of reproductive potential.

Lactation

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

How should this medicine be used?

Darolutamide comes as a tablet to take by mouth. It is usually taken with food twice a day. Take darolutamide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take darolutamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them.

Your doctor may tell you to stop taking darolutamide for a short time or decrease your dose if you experience serious side effects during your treatment. Be sure to talk to your doctor about how you are feeling during your treatment with darolutamide.

If your doctor has prescribed another medication such as goserelin (Zoladex), histrelin (Supprelin LA, Vantas), leuprolide (Eligard, Lupron), or triptorelin (Trelstar) to treat your prostate cancer, you will need to continue receiving this medication during your treatment with darolutamide.

Continue to take darolutamide even if you feel well. Do not stop taking darolutamide without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking darolutamide,

  • tell your doctor and pharmacist if you are allergic to darolutamide, any other medications, or any of the ingredients in darolutamide tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor what herbal products you are taking, especially St. John’s Wort.
  • tell your doctor if you have or have ever had kidney disease, liver disease, heart disease, high blood pressure, diabetes, high blood cholesterol or history of seizures.
  • you should know that darolutamide is only for use in men. Women should not take this medication, especially if they are or may become pregnant or are breastfeeding. If taken by pregnant women, darolutamide may harm the fetus. If a pregnant woman takes darolutamide, she should call her doctor immediately. If your female partner is not pregnant but could become pregnant, you and your partner must use birth control during your treatment and for 1 week after your final dose.
  • you should know that this medication may decrease fertility in men. However, you should not assume that your female partner cannot become pregnant during your treatment.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212099s002lbl.pdf
  3. https://go.drugbank.com/drugs/DB12941
  4. https://en.wikipedia.org/wiki/Darolutamide
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Darolutamide
  6. https://www.drugs.com/mtm/darolutamide.html
  7. https://www.mayoclinic.org/drugs-supplements/darolutamide-oral-route/side-effects/drg-20470011?p=1
  8. https://medlineplus.gov/druginfo/meds/a619045.html
  9. https://www.webmd.com/drugs/2/drug-177648/darolutamide-oral/details/list-contraindications
  10. ChemIDplus Chemical Information Classification
  11. CompTox Chemicals Dashboard Chemical Lists
  12. Guide to Pharmacology Target Classification
  13. NCI Thesaurus Tree
  14. PubChem
  15. Therapeutic category of drugs in Japan
    Anatomical Therapeutic Chemical (ATC) classification
    Target-based classification of drugs

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Darolutamide – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than [apalutamide] and [enzalutamide], which are other androgen receptor antagonists. Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time. Indications This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer. Nubeqa is indicated for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease. Darolutamide is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral orchiectomy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate-specific antigen (PSA) levels through potent androgen receptor antagonism. Darolutamide is an androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer and metastatic hormone-sensitive prostate cancer. Metastatic Hormone Sensitive Prostate Cancer Non-mestatatic castrate-resistant prostate cancer Use in Cancer Darolutamide is approved to treat: Prostate cancer. It is used in adults whose cancer: Has spread to other parts of the body and responds to treatment that lowers testosterone levels. It is used with docetaxel. Has not spread to other parts of the body and no longer responds to treatment that lowers testosterone levels. Darolutamide is also being studied in the treatment of other types of cancer. Contraindications excessive fat in the blood a low seizure threshold high blood pressure coronary artery disease seizures pregnancy chronic kidney disease stage 4 (severe) Child-Pugh class B liver impairment Dosage Strengths: 300 mg Prostate Cancer 600 mg orally 2 times a day Patients receiving this drug should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy. For nonmetastatic castration-resistant prostate cancer (nmCRPC) Renal Dose Adjustments Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended. Severe renal impairment (CrCl 15 to 29 mL/min) who are not receiving hemodialysis: 300 mg orally 2 times a da End-stage renal disease (CrCl 15 mL/min or less): Data not available Liver Dose Adjustments Mild (Child-Pugh A) hepatic impairment: No adjustment recommended. Moderate (Child-Pugh B) hepatic impairment: 300 mg orally 2 times daily Severe (Child-Pugh C) hepatic impairment: Data not available Dose Adjustments Grade 3 or greater toxicity or an intolerable adverse reaction: Withhold therapy or reduce to the dose to 300 mg 2 times a day until symptoms improve; then resume therapy at 600 mg orally 2 times a day. Dose reduction below 300 mg orally 2 times a day is not recommended. Administration advice: This drug should be taken with food. Swallow tablets whole; do not divide, crush, or chew. If a dose is missed it should be taken as soon as it is remembered prior to the next scheduled dose; do not take 2 doses together to make up for a missed dose. Side Effects The Most Common extreme tiredness arm, leg, hand, or foot pain arm, leg, hand, or foot pain rash blood in urine fever, rapid and/or shallow breathing, or cough chest pain or feeling of pressure in the chest seizures severe ongoing nausea or diarrhea; painful or difficult urination; blood in your urine; severe headache, blurred vision, pounding in your neck or ears; slow heart rate, weak pulse, fainting, slow breathing (breathing may stop); signs of a blood clot in the lung--chest pain, sudden cough, wheezing, rapid breathing, coughing up blood; or signs of a lung infection--fever, chills, cough with mucus, chest pain, shortness of breath. More common Black, tarry stools bleeding gums blood in the urine bloody nose blurred vision coughing or spitting up blood difficulty in breathing or swallowing dizziness frequent urination headache increased menstrual flow or vaginal bleeding lower abdominal or stomach cramping nausea and vomiting nervousness nosebleeds painful urination paralysis pounding in the ears prolonged bleeding from cuts red or dark brown urine red or black, tarry stools slow, fast, or irregular heartbeat vomiting of blood or material that looks like coffee grounds unusual bleeding or bruising Rare Blood in the urine chest pain or discomfort pain in the shoulders, arms, jaw, or neck painful or difficult urination seizures sweating trouble breathing Constipation decreased appetite increased weight pain in the arms or legs rash unusual tiredness or weakness Chest pain or tightness cough fever or chills muscle or bone pain sneezing sore throat Drug Interaction DRUG INTERACTION Abametapir The serum concentration of Darolutamide can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Darolutamide. Abrocitinib The serum concentration of Darolutamide can be increased when it is combined with Abrocitinib. Adenine The metabolism of Darolutamide can be decreased when combined with Adenine. Afatinib The serum concentration of Afatinib can be increased when it is combined with Darolutamide. Alectinib Alectinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Allopurinol The serum concentration of Allopurinol can be increased when it is combined with Darolutamide. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Darolutamide. Ambrisentan The serum concentration of Darolutamide can be increased when it is combined with Ambrisentan. Amiodarone The serum concentration of Darolutamide can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Darolutamide can be decreased when combined with Amitriptyline. Amprenavir The serum concentration of Darolutamide can be increased when it is combined with Amprenavir. Apalutamide The serum concentration of Darolutamide can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Apixaban can be increased when it is combined with Darolutamide. Aprepitant The metabolism of Darolutamide can be decreased when combined with Aprepitant. Arsenic trioxide The serum concentration of Darolutamide can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Articaine. Asciminib The serum concentration of Darolutamide can be increased when it is combined with Asciminib. Asunaprevir The serum concentration of Darolutamide can be increased when it is combined with Asunaprevir. Atazanavir The serum concentration of Darolutamide can be increased when it is combined with Atazanavir. Atogepant The serum concentration of Atogepant can be increased when it is combined with Darolutamide. Atorvastatin The excretion of Atorvastatin can be decreased when combined with Darolutamide. Avanafil The serum concentration of Avanafil can be increased when it is combined with Darolutamide. Avatrombopag Avatrombopag may decrease the excretion rate of Darolutamide which could result in a higher serum level. Axitinib The serum concentration of Axitinib can be increased when it is combined with Darolutamide. Beclomethasone Beclomethasone dipropionate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Belantamab mafodotin The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide. Belinostat The serum concentration of Darolutamide can be increased when it is combined with Belinostat. Belumosudil Belumosudil may decrease the excretion rate of Darolutamide which could result in a higher serum level. Bempedoic acid The excretion of Bempedoic acid can be decreased when combined with Darolutamide. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Darolutamide. Benzocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Benzyl alcohol. Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Darolutamide. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Darolutamide. Betrixaban The serum concentration of Darolutamide can be increased when it is combined with Betrixaban. Bexarotene The serum concentration of Darolutamide can be decreased when it is combined with Bexarotene. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Darolutamide. Bisoprolol The serum concentration of Darolutamide can be increased when it is combined with Bisoprolol. Boceprevir The serum concentration of Darolutamide can be increased when it is combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Darolutamide. Bosentan The serum concentration of Darolutamide can be decreased when it is combined with Bosentan. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Darolutamide. Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Darolutamide. Brigatinib The serum concentration of Brigatinib can be increased when it is combined with Darolutamide. Brincidofovir The serum concentration of Brincidofovir can be increased when it is combined with Darolutamide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Darolutamide which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Butamben. Cabazitaxel Cabazitaxel may decrease the excretion rate of Darolutamide which could result in a higher serum level. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Darolutamide. Caffeine Caffeine may decrease the excretion rate of Darolutamide which could result in a higher serum level. Canagliflozin The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin. Cannabidiol Cannabidiol may decrease the excretion rate of Darolutamide which could result in a higher serum level. Capmatinib The serum concentration of Darolutamide can be increased when it is combined with Capmatinib. Capromab pendetide Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. Capsaicin The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Capsaicin. Carbamazepine The serum concentration of Darolutamide can be decreased when it is combined with Carbamazepine. Carfilzomib The serum concentration of Darolutamide can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Darolutamide can be increased when it is combined with Carvedilol. Caspofungin The excretion of Caspofungin can be decreased when combined with Darolutamide. Celecoxib The serum concentration of Celecoxib can be increased when it is combined with Darolutamide. Cenobamate The serum concentration of Darolutamide can be decreased when it is combined with Cenobamate. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Darolutamide. Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Darolutamide. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Chloroprocaine. Cholecystokinin The excretion of Cholecystokinin can be decreased when combined with Darolutamide. Cholesterol Cholesterol may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid The excretion of Cholic Acid can be decreased when combined with Darolutamide. Choline C 11 Darolutamide may decrease effectiveness of Choline C 11 as a diagnostic agent. Cinchocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Cinchocaine. Ciprofloxacin The metabolism of Darolutamide can be decreased when combined with Ciprofloxacin. Cladribine The serum concentration of Cladribine can be increased when it is combined with Darolutamide. Clarithromycin The serum concentration of Darolutamide can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Darolutamide can be increased when it is combined with Clobazam. Clofarabine Darolutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine Clofazimine may decrease the excretion rate of Darolutamide which could result in a higher serum level. Clomifene The serum concentration of Darolutamide can be increased when it is combined with Clomifene. Clozapine The metabolism of Darolutamide can be decreased when combined with Clozapine. Cobicistat The serum concentration of Darolutamide can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Darolutamide. Cocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Cocaine. Colchicine The serum concentration of Darolutamide can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Darolutamide can be increased when it is combined with Conivaptan. Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Darolutamide. Copanlisib Darolutamide may decrease the excretion rate of Copanlisib which could result in a higher serum level. Crizotinib The metabolism of Darolutamide can be decreased when combined with Crizotinib. Curcumin The serum concentration of Darolutamide can be increased when it is combined with Curcumin. Cyclosporine The metabolism of Darolutamide can be decreased when combined with Cyclosporine. Dabigatran etexilate The serum concentration of Darolutamide can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Dabrafenib can be increased when it is combined with Darolutamide. Daclatasvir Daclatasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Dacomitinib The serum concentration of Dacomitinib can be increased when it is combined with Darolutamide. Dactinomycin Darolutamide may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Danazol The serum concentration of Darolutamide can be increased when it is combined with Danazol. Daptomycin The serum concentration of Darolutamide can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Darolutamide. Darunavir The serum concentration of Darolutamide can be increased when it is combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Darolutamide. Daunorubicin Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Deferasirox The metabolism of Darolutamide can be decreased when combined with Deferasirox. Delafloxacin The serum concentration of Delafloxacin can be increased when it is combined with Darolutamide. Delavirdine The serum concentration of Darolutamide can be increased when it is combined with Delavirdine. Desogestrel The metabolism of Darolutamide can be increased when combined with Desogestrel. Desvenlafaxine The metabolism of Darolutamide can be decreased when combined with Desvenlafaxine. Dexamethasone The serum concentration of Darolutamide can be decreased when it is combined with Dexamethasone. Dexamethasone The serum concentration of Darolutamide can be decreased when it is combined with Dexamethasone acetate. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Darolutamide which could result in a higher serum level. Diflunisal The metabolism of Darolutamide can be decreased when combined with Diflunisal. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Darolutamide. Digoxin The serum concentration of Digoxin can be increased when it is combined with Darolutamide. Diltiazem The metabolism of Darolutamide can be decreased when combined with Diltiazem. Dinoprostone The excretion of Dinoprostone can be decreased when combined with Darolutamide. Diosmin The serum concentration of Darolutamide can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Diphenhydramine. Docetaxel The excretion of Docetaxel can be decreased when combined with Darolutamide. Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Darolutamide. Donepezil The serum concentration of Donepezil can be increased when it is combined with Darolutamide. Doxorubicin Darolutamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Dronedarone The metabolism of Darolutamide can be decreased when combined with Dronedarone. Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Darolutamide. Dyclonine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Dyclonine. Echinacea The serum concentration of Darolutamide can be decreased when it is combined with Echinacea. Econazole The serum concentration of Darolutamide can be increased when it is combined with Econazole. Edoxaban The serum concentration of Darolutamide can be increased when it is combined with Edoxaban. Efavirenz The serum concentration of Darolutamide can be decreased when it is combined with Efavirenz. Elagolix The serum concentration of Darolutamide can be increased when it is combined with Elagolix. Elbasvir Elbasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Eliglustat The serum concentration of Darolutamide can be increased when it is combined with Eliglustat. Eltrombopag Eltrombopag may decrease the excretion rate of Darolutamide which could result in a higher serum level. Eluxadoline The serum concentration of Eluxadoline can be increased when it is combined with Darolutamide. Elvitegravir The serum concentration of Darolutamide can be increased when it is combined with Elvitegravir. Enalapril The excretion of Enalapril can be decreased when combined with Darolutamide. Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Darolutamide. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be increased when it is combined with Darolutamide. Entrectinib The serum concentration of Darolutamide can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Darolutamide can be decreased when it is combined with Enzalutamide. Erdafitinib The serum concentration of Darolutamide can be increased when it is combined with Erdafitinib. Ergotamine The serum concentration of Darolutamide can be increased when it is combined with Ergotamine. Erlotinib Erlotinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Darolutamide. Erythromycin The metabolism of Darolutamide can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Darolutamide. Estradiol Estradiol may decrease the excretion rate of Darolutamide which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Darolutamide which could result in a higher serum level. Ethinylestradiol The metabolism of Darolutamide can be increased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Etidocaine. Etoposide The serum concentration of Etoposide can be increased when it is combined with Darolutamide. Etravirine The serum concentration of Darolutamide can be decreased when it is combined with Etravirine. Everolimus The serum concentration of Darolutamide can be increased when it is combined with Everolimus. Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Darolutamide. Favipiravir The serum concentration of Darolutamide can be increased when it is combined with Favipiravir. Febuxostat The excretion of Darolutamide can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Fexofenadine The serum concentration of Darolutamide can be increased when it is combined with Fexofenadine. Flibanserin The serum concentration of Darolutamide can be increased when it is combined with Flibanserin. Fluconazole The metabolism of Darolutamide can be decreased when combined with Fluconazole. Flunitrazepam The metabolism of Darolutamide can be decreased when combined with Flunitrazepam. Fluorouracil The serum concentration of Fluorouracil can be increased when it is combined with Darolutamide. Flurbiprofen The metabolism of Darolutamide can be decreased when combined with Flurbiprofen. Fluvastatin The excretion of Fluvastatin can be decreased when combined with Darolutamide. Fluvoxamine The metabolism of Darolutamide can be decreased when combined with Fluvoxamine. Folic acid The serum concentration of Folic acid can be increased when it is combined with Darolutamide. Fosnetupitant The metabolism of Darolutamide can be decreased when combined with Fosnetupitant. Fosphenytoin The serum concentration of Darolutamide can be decreased when it is combined with Fosphenytoin. Fostamatinib Fostamatinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Darolutamide. Fusidic acid The metabolism of Darolutamide can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Darolutamide. Gadoxetic acid The excretion of Gadoxetic acid can be decreased when combined with Darolutamide. Gallium Ga-68 Darolutamide may increase effectiveness of Gallium Ga-68 gozetotide as a diagnostic agent. Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Darolutamide. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Darolutamide. Gemfibrozil The metabolism of Darolutamide can be decreased when combined with Gemfibrozil. Gilteritinib Gilteritinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Glasdegib The serum concentration of Glasdegib can be increased when it is combined with Darolutamide. Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Darolutamide. Glyburide The serum concentration of Glyburide can be increased when it is combined with Darolutamide. Grazoprevir Grazoprevir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Darolutamide. Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Darolutamide. Imatinib The serum concentration of Imatinib can be increased when it is combined with Darolutamide. Imipramine The serum concentration of Imipramine can be increased when it is combined with Darolutamide. Indacaterol The serum concentration of Darolutamide can be increased when it is combined with Indacaterol. Indinavir The serum concentration of Darolutamide can be increased when it is combined with Indinavir. Indomethacin The metabolism of Darolutamide can be decreased when combined with Indomethacin. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Darolutamide. Irinotecan Darolutamide may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The serum concentration of Darolutamide can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Darolutamide can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Darolutamide can be decreased when combined with Isoniazid. Isradipine The metabolism of Darolutamide can be decreased when combined with Isradipine. Istradefylline Istradefylline may decrease the excretion rate of Darolutamide which could result in a higher serum level. Itraconazole The serum concentration of Darolutamide can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Darolutamide can be increased when it is combined with Ivacaftor. Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Darolutamide. Ivosidenib The metabolism of Darolutamide can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Darolutamide can be increased when it is combined with Ixabepilone. Ketoconazole The serum concentration of Darolutamide can be increased when it is combined with Ketoconazole. Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Darolutamide. Lamotrigine The metabolism of Darolutamide can be increased when combined with Lamotrigine. Lansoprazole Lansoprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. Lapatinib The serum concentration of Darolutamide can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Darolutamide. Lasmiditan The serum concentration of Darolutamide can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Lefamulin The serum concentration of Darolutamide can be increased when it is combined with Lefamulin. Leflunomide The serum concentration of Leflunomide can be increased when it is combined with Darolutamide. Lemborexant The serum concentration of Darolutamide can be increased when it is combined with Lemborexant. Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Darolutamide. Letermovir Letermovir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Levobupivacaine. Levoketoconazole The serum concentration of Darolutamide can be increased when it is combined with Levoketoconazole. Levosalbutamol The excretion of Levosalbutamol can be decreased when combined with Darolutamide. Lidocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Lidocaine. Linagliptin The metabolism of Darolutamide can be decreased when combined with Linagliptin. Liothyronine The excretion of Liothyronine can be decreased when combined with Darolutamide. Liotrix The excretion of Liotrix can be decreased when combined with Darolutamide. Lomitapide The serum concentration of Darolutamide can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Darolutamide can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Darolutamide. Loperamide The serum concentration of Darolutamide can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Darolutamide can be increased when it is combined with Lopinavir. Lovastatin The metabolism of Darolutamide can be decreased when combined with Lovastatin. Loxapine The serum concentration of Darolutamide can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Darolutamide can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Darolutamide. Mannitol The serum concentration of Darolutamide can be increased when it is combined with Mannitol. Maribavir Maribavir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Mavacamten The serum concentration of Darolutamide can be decreased when it is combined with Mavacamten. Mefenamic acid The metabolism of Darolutamide can be decreased when combined with Mefenamic acid. Mefloquine The serum concentration of Darolutamide can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Mepivacaine. Methimazole The serum concentration of Darolutamide can be increased when it is combined with Methimazole. Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Darolutamide. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Darolutamide. Methylene blue The serum concentration of Darolutamide can be increased when it is combined with Methylene blue. Metreleptin The metabolism of Darolutamide can be increased when combined with Metreleptin. Miconazole The metabolism of Darolutamide can be decreased when combined with Miconazole. Midostaurin The serum concentration of Darolutamide can be decreased when it is combined with Midostaurin. Mifepristone The serum concentration of Darolutamide can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Darolutamide can be decreased when combined with Milnacipran. Mirabegron The serum concentration of Darolutamide can be increased when it is combined with Mirabegron. Mitapivat The metabolism of Darolutamide can be increased when combined with Mitapivat. Mitotane The serum concentration of Darolutamide can be decreased when it is combined with Mitotane. Mitoxantrone Darolutamide may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Modafinil The serum concentration of Darolutamide can be decreased when it is combined with Modafinil. Morphine The serum concentration of Darolutamide can be increased when it is combined with Morphine. Mycophenolate The serum concentration of Mycophenolate mofetil can be increased when it is combined with Darolutamide. Nafcillin The serum concentration of Darolutamide can be decreased when it is combined with Nafcillin. Naloxone The serum concentration of Darolutamide can be increased when it is combined with Naloxone. Nefazodone The serum concentration of Darolutamide can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Darolutamide can be increased when it is combined with Nelfinavir. Neratinib The serum concentration of Darolutamide can be increased when it is combined with Neratinib. Netupitant The metabolism of Darolutamide can be decreased when combined with Netupitant. Nicardipine The metabolism of Darolutamide can be decreased when combined with Nicardipine. Nilotinib The serum concentration of Darolutamide can be increased when it is combined with Nilotinib. Nilvadipine The metabolism of Darolutamide can be decreased when combined with Nilvadipine. Nintedanib The serum concentration of Darolutamide can be increased when it is combined with Nintedanib. Nitrofurantoin The serum concentration of Nitrofurantoin can be increased when it is combined with Darolutamide. Norgestimate The serum concentration of Darolutamide can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Darolutamide. Novobiocin Novobiocin may decrease the excretion rate of Darolutamide which could result in a higher serum level. Omadacycline The serum concentration of Darolutamide can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Darolutamide. Omeprazole Omeprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Darolutamide. Oteseconazole The serum concentration of Darolutamide can be increased when it is combined with Oteseconazole. Ouabain The excretion of Ouabain can be decreased when combined with Darolutamide. Oxaliplatin Darolutamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Oxybuprocaine. Ozanimod Darolutamide may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The excretion of Paclitaxel can be decreased when combined with Darolutamide. Pacritinib The serum concentration of Darolutamide can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Darolutamide. Paliperidone The serum concentration of Darolutamide can be increased when it is combined with Paliperidone. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Darolutamide. Pantoprazole Pantoprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. Paritaprevir Paritaprevir may decrease the excretion rate of Darolutamide which could result in a higher serum level. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Darolutamide. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Darolutamide. Penicillamine The excretion of Penicillamine can be decreased when combined with Darolutamide. Pentobarbital The serum concentration of Darolutamide can be decreased when it is combined with Pentobarbital. Pexidartinib The metabolism of Darolutamide can be decreased when combined with Pexidartinib. Phenobarbital The serum concentration of Darolutamide can be decreased when it is combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Phenol. Phenytoin The serum concentration of Darolutamide can be decreased when it is combined with Phenytoin. Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Darolutamide. Piflufolastat F 18 Darolutamide may decrease effectiveness of Piflufolastat F 18 as a diagnostic agent. Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Darolutamide. Pitolisant The serum concentration of Darolutamide can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Darolutamide. Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Darolutamide. Posaconazole The serum concentration of Darolutamide can be increased when it is combined with Posaconazole. Pralatrexate Darolutamide may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Darolutamide. Pramocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Pramocaine. Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Darolutamide. Prazosin The serum concentration of Prazosin can be increased when it is combined with Darolutamide. Prednisolone The serum concentration of Prednisolone phosphate can be increased when it is combined with Darolutamide. Prilocaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Prilocaine. Primaquine The metabolism of Darolutamide can be decreased when combined with Primaquine. Primidone The serum concentration of Darolutamide can be decreased when it is combined with Primidone. Probenecid The metabolism of Darolutamide can be decreased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Procaine. Progesterone Progesterone may decrease the excretion rate of Darolutamide which could result in a higher serum level. Propafenone The serum concentration of Darolutamide can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Proparacaine. Propofol The metabolism of Darolutamide can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Propoxycaine. Quinidine The serum concentration of Darolutamide can be increased when it is combined with Quinidine. Quinine The serum concentration of Darolutamide can be increased when it is combined with Quinine. Rabeprazole Rabeprazole may decrease the excretion rate of Darolutamide which could result in a higher serum level. Raloxifene The serum concentration of Raloxifene can be increased when it is combined with Darolutamide. Ranolazine The serum concentration of Darolutamide can be increased when it is combined with Ranolazine. Regorafenib Regorafenib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Relugolix The serum concentration of Darolutamide can be increased when it is combined with Relugolix. Repaglinide The excretion of Repaglinide can be decreased when combined with Darolutamide. Reserpine The serum concentration of Darolutamide can be increased when it is combined with Reserpine. Revefenacin Darolutamide may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The serum concentration of Darolutamide can be increased when it is combined with Ribociclib. Rifampicin The serum concentration of Darolutamide can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Darolutamide can be decreased when it is combined with Rifamycin. Rifapentine The serum concentration of Darolutamide can be decreased when it is combined with Rifapentine. Rilpivirine Rilpivirine may decrease the excretion rate of Darolutamide which could result in a higher serum level. Riluzole The serum concentration of Riluzole can be increased when it is combined with Darolutamide. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Darolutamide. Rimexolone The serum concentration of Darolutamide can be decreased when it is combined with Rimexolone. Riociguat The serum concentration of Riociguat can be increased when it is combined with Darolutamide. Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Darolutamide. Ritonavir The serum concentration of Darolutamide can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Darolutamide. Rolapitant Rolapitant may decrease the excretion rate of Darolutamide which could result in a higher serum level. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Darolutamide. Ropivacaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Ropivacaine. Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Darolutamide. Roxadustat The serum concentration of Darolutamide can be increased when it is combined with Roxadustat. Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Darolutamide. Safinamide Safinamide may decrease the excretion rate of Darolutamide which could result in a higher serum level. Sapropterin The serum concentration of Darolutamide can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Darolutamide can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Darolutamide can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Darolutamide can be decreased when it is combined with Satralizumab. Selexipag The serum concentration of Darolutamide can be increased when it is combined with Selexipag. Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Darolutamide. Sildenafil The serum concentration of Darolutamide can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Darolutamide can be increased when it is combined with Silodosin. Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Darolutamide. Simvastatin The serum concentration of Darolutamide can be increased when it is combined with Simvastatin. Sincalide The excretion of Sincalide can be decreased when combined with Darolutamide. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Darolutamide. Sitagliptin The serum concentration of Darolutamide can be increased when it is combined with Sitagliptin. Sodium The metabolism of Darolutamide can be decreased when combined with Sodium aurothiomalate. Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Darolutamide. Somatrogon The metabolism of Darolutamide can be increased when combined with Somatrogon. Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Darolutamide. Sotagliflozin Sotagliflozin may decrease the excretion rate of Darolutamide which could result in a higher serum level. Sotorasib The serum concentration of Darolutamide can be decreased when it is combined with Sotorasib. St. John's Wort The serum concentration of Darolutamide can be decreased when it is combined with St. John's Wort. Stiripentol The serum concentration of Darolutamide can be increased when it is combined with Stiripentol. Sulfasalazine The serum concentration of Sulfasalazine can be increased when it is combined with Darolutamide. Sumatriptan The serum concentration of Sumatriptan can be increased when it is combined with Darolutamide. Sunitinib Sunitinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Suvorexant The serum concentration of Darolutamide can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Darolutamide can be increased when it is combined with Tacrolimus. Tafamidis The serum concentration of Darolutamide can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Darolutamide. Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Darolutamide. Taurocholic acid Taurocholic acid may decrease the excretion rate of Darolutamide which could result in a higher serum level. Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Darolutamide. Technetium The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Darolutamide. Technetium The serum concentration of Darolutamide can be increased when it is combined with Technetium Tc-99m sestamibi. Tegaserod The serum concentration of Tegaserod can be increased when it is combined with Darolutamide. Telaprevir The serum concentration of Darolutamide can be increased when it is combined with Telaprevir. Telithromycin The serum concentration of Darolutamide can be increased when it is combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Darolutamide which could result in a higher serum level. Telotristat ethyl The serum concentration of Darolutamide can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Darolutamide can be increased when it is combined with Temsirolimus. Teniposide Darolutamide may decrease the excretion rate of Teniposide which could result in a higher serum level. Tenofovir The serum concentration of Tenofovir alafenamide can be increased when it is combined with Darolutamide. Tenofovir disoproxil The serum concentration of Darolutamide can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Darolutamide can be increased when it is combined with Tepotinib. Terfenadine The serum concentration of Darolutamide can be increased when it is combined with Terfenadine. Teriflunomide The serum concentration of Teriflunomide can be increased when it is combined with Darolutamide. Testosterone The serum concentration of Testosterone can be increased when it is combined with Darolutamide. Testosterone Darolutamide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Darolutamide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone The metabolism of Darolutamide can be increased when combined with Testosterone propionate. Tetracaine The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Tetracaine. Tezacaftor The serum concentration of Darolutamide can be increased when it is combined with Tezacaftor. Ticagrelor The serum concentration of Darolutamide can be increased when it is combined with Ticagrelor. Tipranavir The serum concentration of Darolutamide can be increased when it is combined with Tipranavir. Tivozanib Tivozanib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Darolutamide. Topotecan The serum concentration of Topotecan can be increased when it is combined with Darolutamide. Torasemide The excretion of Torasemide can be decreased when combined with Darolutamide. Toremifene The serum concentration of Darolutamide can be increased when it is combined with Toremifene. Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Darolutamide. Trilaciclib Darolutamide may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Darolutamide. Troleandomycin The serum concentration of Darolutamide can be increased when it is combined with Troleandomycin. Tucatinib The serum concentration of Tucatinib can be increased when it is combined with Darolutamide. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Darolutamide. Umbralisib The serum concentration of Darolutamide can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Darolutamide can be increased when it is combined with Umeclidinium. Valproic acid The metabolism of Darolutamide can be decreased when combined with Valproic acid. Valsartan The excretion of Valsartan can be decreased when combined with Darolutamide. Vandetanib Vandetanib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Vardenafil The serum concentration of Darolutamide can be increased when it is combined with Vardenafil. Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Darolutamide. Vemurafenib The serum concentration of Darolutamide can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Darolutamide. Venlafaxine Venlafaxine may increase the excretion rate of Darolutamide which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The metabolism of Darolutamide can be decreased when combined with Verapamil. Viloxazine The metabolism of Darolutamide can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Darolutamide. Vincristine Darolutamide may decrease the excretion rate of Vincristine which could result in a higher serum level. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Darolutamide. Vismodegib Vismodegib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Voclosporin The serum concentration of Darolutamide can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Darolutamide can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Darolutamide can be increased when it is combined with Voriconazole. Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Darolutamide. Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Darolutamide. Zimelidine The metabolism of Darolutamide can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Darolutamide can be decreased when combined with Ziprasidone. Zonisamide The serum concentration of Darolutamide can be increased when it is combined with Zonisamide. Pregnancy and Lactation AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Pregnancy The safety and efficacy of this drug have not been established in females. Based on its mechanism of action, this drug can cause fetal harm and loss of pregnancy. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 1 week after. Based on animal studies, this drug may impair fertility in males of reproductive potential. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How should this medicine be used?

Darolutamide comes as a tablet to take by mouth. It is usually taken with food twice a day. Take darolutamide at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take darolutamide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not split, chew,…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…